Johnson & Johnson has released its latest 13F-HR filing, detailing its investment holdings as of September 30, 2026. This filing is significant as it showcases the company's investment strategy and positions in various securities, which can provide insights into its future direction.
Founded in 1886, Johnson & Johnson is a major player in the pharmaceutical preparations sector, classified under SIC 2834. The company is publicly traded on the New York Stock Exchange under the ticker JNJ. It operates as a large accelerated filer, reflecting its substantial market presence and operational scale.
The recent filing, accession number 0000904454-26-000541, indicates that Johnson & Johnson holds a total value of approximately $761.7 million across various investments. The filing includes details about the company's holdings in multiple firms, such as Adicet Bio Inc, Cerebras Systems Inc, and Fate Therapeutics Inc, among others. Notably, the filing states, "The report type is 13F HOLDINGS REPORT," confirming the nature of the submission.
This filing could impact various stakeholders, including investors, analysts, and competitors in the pharmaceutical preparations industry. Investors may look closely at Johnson & Johnson's holdings for clues about market trends and potential areas of growth. Competitors may analyze the information to gauge Johnson & Johnson's strategic focus and investment priorities.
As for what’s next, the filing does not specify any forthcoming actions or additional filings. However, stakeholders will likely keep a close watch on Johnson & Johnson's future reports for further insights into its investment strategy and market positioning.